In short
Clinical trials investigating XYLOMETAZOLINE HYDROCHLORIDE are studying how it is used in specific patient groups, including people with COPD and patients needing intranasal pain control for nasotracheal intubation. These trials mainly look at physical capacity, pain relief, and study design in Phase 3 interventional research.
Key points
- Clinical trials investigating XYLOMETAZOLINE HYDROCHLORIDE are looking at two different patient settings. One Phase 3 study follows people with Chronic Obstructive Pulmonary Disease (COPD) and measures walking distance as a sign of physical capacity. Another Phase 3 blinded triple crossover study looks at intranasal pain control during nasotracheal intubation and measures pain with a 0 to 100 scale. The studies include patients with COPD and patients having a nasal breathing tube procedure. One trial is authorised and the other is completed. Together, these trials focus on how XYLOMETAZOLINE HYDROCHLORIDE is used in specific clinical situations and what results it may affect.
Trial overview
These records describe interventional clinical trials, which means researchers gave a treatment or procedure and then measured the results. The trials investigate XYLOMETAZOLINE HYDROCHLORIDE in two different clinical settings: COPD and nasotracheal intubation. Both studies are in Phase 3, which is a later stage of testing in people.
COPD study and physical capacity
One trial, NCT 2024-520177-12-00, is an authorised Phase 3 study in people with Chronic Obstructive Pulmonary Disease (COPD). Its goal is to assess the effect of one dose on the physical capacity of patients with COPD. The main result being measured is walking distance, which helps show how far a person can walk as a sign of physical ability.
Intranasal analgesia study during nasotracheal intubation
The second trial, NCT 2023-506644-17-01, is a completed Phase 3 blinded triple crossover study in patients undergoing nasotracheal intubation. A blinded triple crossover study means the treatment order is compared across several approaches, and the people involved do not know which treatment is being given at a given time. This study compares cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia, which means pain relief given through the nose.
Study design and participants
The COPD study includes patients with a long-term lung disease that can make breathing difficult. The intubation study includes patients who need a breathing tube placed through the nose. Together, these trials show that XYLOMETAZOLINE HYDROCHLORIDE is being studied in very different groups of patients rather than in one single disease area.
Endpoints and outcome measures
A primary outcome is the main result a study is designed to measure. In the COPD study, the primary outcome is walking distance. In the intubation study, the primary outcome is self-reported pain during the procedure, measured with a visual analogue scale from 0 to 100. This scale is a simple way for patients to rate pain, with higher numbers showing more pain.
Trial status and enrollment
The COPD study is listed as Authorised and plans to include 64 participants. The intranasal analgesia study is listed as Completed and included 12 participants. Enrollment means the number of people planned or included in a study.